Abeona Therapeutics Inc (ABEO) 시세

all this company has down in the last 3years is give their people raises and incentives and bonuses' if you are a long term investor all you get is stock reversals and b/s promises they are 1 step in front of the law. i hope their watching, if not i'll remind them

ABEO under $7

ABEO under $6

ABEO under $5

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

ABEO new 52+week high

ABEO new 52 week high

ABEO new 52 week high

ABEO new 52 week high

ABEO new 52 week high

ABEO new 52 week high

Of course this goes up after I close my position. ??

You gots me CONFUSED, Young Lady!! YES, I indeed DID post over there --- which YOU should have IGNORED in the first place!! WHATEVER!!! Bottom line???? GO-GO-GO-BABL and HPCO!!! Those two are where I am 'losing-my-shirt' right now!!

you already posted there silly, so i replied to you there in pm. and yes, i know you cant pm back anymore.

O.K., I'll take a look at THAT one right now.

i found it on my…

..

own but got back out, its junk, lol. i was replying to you on the other stock admp.

ABEO: It's pronounced like, "ABALONE" (that Fish thing)!!

PS: I got your PM, but can't reply to it. Bottom line, do NOT "invest" in ANY of my stock picks!! (Which is great advice for ME, too!!)

can anyone pronounce …

..

this?

Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

nice pop in overnight trading. lets see what she does today.

quiet board but this stock is on the move! grabbed a few today.

$3.69 news data coming within a month

Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 upon completion of the last patient monitoring visit, which is expected by mid-September.

Buying $3.01 phase 3 data due anyday 3 mil o/s 3 mill float



Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 upon completion of the last patient monitoring visit, which is expected by mid-September.

We need to get this over $1

Let’s goooo$$$$

Looks good here

ABEO .35 +7%

* * $ABEO Video Chart 02-25-2021 * *

Link to Video - click here to watch the technical chart video

They are MBIO, SIOX, and GTHX. GTHX will be the most successful of the three, as they have a recently-approved drug that will change the face of the use of chemotherapy. It is still amazingly cheap relative to its value, and is an easy three-bagger within at most two years, and probably before that.

Which are those 3?

I had to say goodbye to Abeona earlier this week when its price rose above my basis, as I swore to myself that I would do so if it ever recovered from its rapid decline to $1.00. I split it among three other biopharmas which I think have more immediate prospects of bringing their pipelines to revenue-generating fruition. This is a good company, but I think bringing their pipeline to revenue-generating fruition will take awhile from this point. Michael Amoroso should get a lot of credit for what he's done so far as Abeona's leader. Good luck to all who invest here. You could find a lot worse companies in which to invest.

I like what they're doing and obviously also like the share price movement today. Michael Amoroso should get a lot of credit for the way he was able to turn this situation around.

Apparently from the news today Michael Amoroso does know what he is doing. I had a feeling that they were down but not out. I have a good feeling about the gradual and successful development of their pipeline.

Heck ya

The share price is certainly showing a nice steady increase.

Chart looks to be a nice steady incline here

With today's advance, this has almost doubled from the level to where it fell when the CEO and five directors simultaneously resigned. Hopefully the price advance reflects positive things that Michael Amoroso is doing to develop the company. I've held all my shares through the downturn, and have confidence in his background and the company's pipeline.

strong chart here

I feel like people are sleeping on this one. It was a major shock from which to recover to have the CEO and half of the board resign, but I think Michael Amoroso knows what he is doing and is doing a good job in moving the company forward, and I believe that there is good long-term potential here.

News just out spiking up on it

Wow - nice jump today - up 17%! It's still a long way to my basis of $2.98 per share, but something is afoot here with the kind of volume we saw today.

Nice jump today and up over 50% from its low. Let's hope Michael Amoroso can do something here with the assets and the pipeline. He's certainly got the background to be able to bring it forward.

* * $ABEO Video Chart 11-11-2020 * *

Link to Video - click here to watch the technical chart video

Breaking News: $ABEO What Are The Best Penny Stocks To Buy Now? 3 Biotech Stocks To Watch

3 Biotech Penny Stocks to Watch in 2020 Biotech penny stocks have become some of the most popular choices for all types of investors. Both institutional and retail investors have been working to seek gains in the biotech industry. Since the beginning of the year, investors have turn...

Got this from ABEO - What Are The Best Penny Stocks To Buy Now? 3 Biotech Stocks To Watch

2x813008 shares free options for 1 year, to two directors
WTF

On September 17, 2020, Abeona Therapeutics Inc. (the “Company”) had filed a Current Report on Form 8-K reporting that Steven H. Rouhandeh had notified the Company of his resignation from the Board of Directors (the “Board”), effective September 30, 2020. On September 30, 2020, Mr. Rouhandeh rescinded his resignation from the Board, and the Board accepted his rescission of resignation. Also on September 30, 2020, the Board voted unanimously to elect Mr. Rouhandeh as Chairman of the Board. Mr. Rouhandeh will not be taking on any additional compensation as Chairman other than what he was already receiving as a non-employee director, which such compensation is disclosed in the Company’s proxy statement filed on April 10, 2020.

8k

BREAKING NEWS: $ABEO Abeona Therapeutics' Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan

Steven H. Rouhandeh Appointed as Chairman of the Board of Directors Jefferies LLC R etained as F inancial A dvisor to A ssist with the R eview of S trategic O ptions NEW YORK and CLEVELAND, Oct. 06, 2020 (GLOBE NEWSWI...

Find out more ABEO - Abeona Therapeutics' Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan

Steven Rouhandeh
Founder,Chairman and Chief Investment Officer at SCO Capital Partners
Location: United States

Mr. Steven H. Rouhandeh, also known as Steve, J.D., is the Founder of SCO Capital Partners, LLC and has been its Chairman and Chief Investment Officer since 1997. Mr. Rouhandeh is the Founder of SCO Financial Group, LLC and serves as its Chairman. He has been an Executive Chairman at PlasmaTech Biopharmaceuticals, Inc. since March 4, 2008 and has been its Principal Executive Officer since January 1, 2015.

Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Lead...
October 06 2020 - 04:01PM

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that its Board of Directors has formed a Special Committee to oversee and advise the executive leadership team on the operations of the Company, leveraging the respective medical, business development and financial expertise of its members. The Special Committee, which consists of current board members, is also working closely with the executive leadership team to develop the Company’s strategic direction and leadership plan as it continues to advance its clinical programs toward providing novel gene and cell therapies to patients who currently have no approved treatment options. The Company also announced the appointment of Steven H. Rouhandeh as Chairman of its Board of Directors.

Strategic Review

Abeona has retained Jefferies LLC as its financial advisor to assist with the review of strategic options focused on advancing the Company’s mission and maximizing stakeholder value. There can be no assurance this strategic review will result in the completion of any particular course of action. There is no defined timeline for completion of the review process and the Company does not intend to comment further unless a specific initiative is approved by the Board of Directors, the review process is concluded, or it is otherwise determined that other disclosure is appropriate.

Abeona Therapeutics selloff yesterday an overreaction, says B. Riley FBR 08:00 ABEO B. Riley FBR analyst Justin Zelin lowered the firm's price target on Abeona Therapeutics to $2 from $5 and reiterates a Buy rating on the shares. The company's assets, including manufacturing infrastructure, are worth more than the market's current valuation following yesterday's 41% selloff, Zelin tells investors in a research note. However, to reflect reduced transparency into Abeona's leadership and strategy Zelin lowered his probability of success for lead asset EB-101 from 65% to 50% and from 20% to 15% for AB-102 and AB-101. Nonetheless, the analyst views yesterday's pullback as overreaction and continues to see upside in the shares.

Read more at:
https://thefly.com/n.php?id=3167175